Objective: To study the effect of Qizhu granule on liver function in rats with adriamycin nephropathy. Method: SD rats were randomly divided to six groups:blank group

model group

prednison group 10 mg·kg-1 and Qizhu granule groups with the dosage of 5

10

20 g·kg-1. All animals

except for blank group

had been intravenously injected with drugs to establish the rat model with adriamycin nephropathy. Four weeks later

the serum albumin and lipid levels

liver and kidney functions were measured at the end of the study. The pathological analysis of hepatic and kidney tissues was performed by hematoxylin and easin(HE) staining. The expression of fibronectin (FN) was also measured by immunohistochemical staining. Result: Compared with blank group

the total cholesterol(TCH) and triglycerides(TG) levels in serum and the expression of FN in kidney were significantly increased in model group after the 4-week study (P<0.01)

but the serum albumin levels

liver and kidney functions were significantly decreased (P<0.01). Meanwhile

abnormal pathological changes of hepatic and kidney tissues could be observed by HE staining. Compared with model group

Qizhu granule could significantly decrease the levels of TCH and TG in serum and FN expression in kidney (P<0.05

P<0.01)

increase the serum albumin levels

improve liver and kidney functions and attenuate pathological changes of hepatic and kidney tissues. Conclusion: Qizhu granule can mitigate hypohepatia in rats with adriamycin nephropathy by long-term administration.